1. All Products
  2. MILTEFOSINE, 10mg, caps.
Public Pricelist

MILTEFOSINE, 10mg, caps.

https://unicat.msf.org/cat/product/12177
STD DORAMILT1C-

Valid Article

Former Code(s): -X
Article is intended to be used with children (<12 years) ONLY.
6.5.2 - Antileishmaniasis medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
P01CX04
Anatomical Therapeutic Chemical Classification according to WHOCC
P
The order of this product needs to be justified and is only acceptable under certain conditions.
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

MILTEFOSINE

Therapeutic Action

Antimicrobial, anti-leishmanial, antineoplastic

Indications

Visceral leishmaniasis in East Africa, in HIV co-infected patients, in association with liposomal amphotericin B

Post-kala azar dermal leishmaniasis in East Africa, in HIV co-infected patients, in association with pentavalent antimonial

Cutaneous leishmaniasis

Some restricted information has been hidden. Sign in to see this information

Instructions for use

The capsule should be swallowed whole and not chewed or broken apart. To be administered with food to reduce gastrointestinal side effects.

The 10 mg dosage is intended for paediatric use.

Precautions for Use

Contraindicated during pregnancy due to potential risk of embryo-fetal toxicity, including death and foetal malformations.

Vomiting and/or diarrhoea occurring during treatment may affect absorption of oral contraceptives and therefore compromise their efficacy. Advise women of childbearing age to use an additional non-oral method of effective contraception during treatment and for 5 months after the last dose.

Do not administer in children under 12 years of age or weighing less than 30 kg.

Common side effects: abdominal pain, nausea, vomiting, and diarrhoea.

Storage

Below 25ºC- Protect from humidity